Results 11 to 20 of about 715,934 (277)

Managing end-stage carcinoid heart disease: A case report and literature review. [PDF]

World J Gastrointest Oncol
BACKGROUND Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) are rare tumors, often diagnosed in an advanced stage when curative treatment is impossible and grueling symptoms related to vasoactive substance release by tumor cells affect patients’
Bulj N, Tomasic V, Cigrovski Berkovic M.
europepmc   +3 more sources

Late-onset multivalvular carcinoid heart disease. [PDF]

Arch Cardiol Mex
We present a 60-year-old man with an 11-year history of an ileocecal neuroendocrine tumor (NET) with a 1% proliferation index (Ki-67) and carcinoid syndrome (CS ...
Rivera K, Zielonka M, Ramírez-Martínez T, Pueyo-Balsells N, Fernández-Rodríguez D.   +4 more
europepmc   +4 more sources

Quadruple Valve Replacement for Carcinoid Heart Disease [PDF]

Brazilian Journal of Cardiovascular Surgery, 2018
Introduction: Carcinoid heart disease most frequently involves the tricuspid or, more rarely, the pulmonary valve and presents with right heart failure as 5-HT is metabolized by the lung. Left-sided valve involvement is quite rare.
Syed Saleem Mujtaba, Stephen Clark
doaj   +3 more sources

Late-stage diagnosis of carcinoid heart disease due to lack of access to health care [PDF]

Cardio-Oncology, 2023
Carcinoid syndrome (CS) is a unique constellation of symptoms caused by release of vasoactive substances from neuroendocrine tumors (Pandit et al., StatPearls, 2022).
Aditi Sharma, Maria E. Fierro, Stella Pak, Keerthi Thallapureddy, Moyosore Awobajo, Dawn Hui, Prince Otchere   +6 more
doaj   +3 more sources

Carcinoid heart disease in patients with advanced small-intestinal neuroendocrine tumors and carcinoid syndrome: a retrospective experience from two European referral centers. [PDF]

ESMO Open
Algeri L, Falkman L, Spada F, Frassoni S, Bagnardi V, Boselli S, Cardinale D, Zanobini M, Crona J, Benini L, Tamayo D, Mazzon C, Gervaso L, Cella CA, Zampino MG, Ciardiello D, Russo A, Badalamenti G, Welin S, Fazio N.   +19 more
europepmc   +3 more sources

Does Telotristat Have a Role in Preventing Carcinoid Heart Disease? [PDF]

Int J Mol Sci
Carcinoid heart disease (CHD) is a frequent and life-threatening complication in patients with carcinoid tumors. Its clinical management is challenging is some cases since serotonin-induced valve fibrosis leads to heart failure.
Herrera-Martínez AD, Fuentes-Fayos AC, Sanchez-Sanchez R, Montero AJ, Sarmento-Cabral A, Gálvez-Moreno MA, Gahete MD, Luque RM.   +7 more
europepmc   +2 more sources

Carcinoid Heart Disease Management: A Multi-Disciplinary Collaboration. [PDF]

Oncologist, 2023
Carcinoid heart disease (CaHD) is an important complication among patients with metastatic neuroendocrine tumors and carcinoid syndrome (CS). CS patients (25%-65%) eventually develop CaHD; these patients face a significantly increased risk of morbidity ...
Das S, Stockton SS, Hassan SA.
europepmc   +2 more sources

Carcinoid heart disease revealed by cyanosis with both right and left valvular involvement: a case report [PDF]

Journal of Medical Case Reports, 2018
Background Carcinoid heart disease is a frequent complication of carcinoid syndrome. It is related to the release by the carcinoid tumor and/or its metastases of bioactive substances such as serotonin.
Khadija Khay, Salim Arous, Tarik Bentaoune, Abdenasser Drighil, Rachida Habbal   +4 more
doaj   +2 more sources

Bioprosthetic valve monitoring in patients with carcinoid heart disease. [PDF]

Front Cardiovasc Med, 2022
Background Carcinoid heart disease (CnHD) is a frequent cause of morbidity and mortality in patients with neuroendocrine tumors and carcinoid syndrome. Although valve replacement surgery appears to decrease all-cause mortality in patients with advanced ...
Honan KA, Hassan S, Deswal A, Herrmann J, Song J, Monlezun D, Halperin D, Mahvash A, Dasari A, Koutroumpakis E, Akay M, Balanescu DV, de Armas IS, Patel M, Nathan S, Kar B, Marmagkiolis K, Lopez-Mattei J, Patel J, Gregoric I, Yao J, Iliescu CA.   +21 more
europepmc   +2 more sources

Prevalence, one-year-incidence and predictors of carcinoid heart disease. [PDF]

Cardiovasc Ultrasound, 2023
Background Carcinoid heart disease (CHD) caused by neuroendocrine tumours (NET) is associated with an increased morbidity and mortality due to valvular dysfunction and right sided heart failure.
Mattig I, Franke MR, Pschowski R, Brand A, Stangl K, Knebel F, Dreger H.   +6 more
europepmc   +2 more sources